Blood Cancers Today Associate Editor Thomas Martin, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the key highlights in multiple myeloma from the summer conference season.
Dr. Martin speaks about major updates and sessions from the 2023 American Society of Clinical Oncology Meeting, the International Myeloma Working Group meeting, and the 2023 European Hematology Association Congress.
“It was a tremendous meeting with over 100 myeloma specialists throughout the world,” Dr. Martin said of the International Myeloma Working Group meeting.
He also highlighted data from the randomized phase III CARTITUDE-4 study and its implications for moving chimeric antigen receptor (CAR) T-cell therapy into earlier lines of treatment in multiple myeloma.
“The exciting news was that the data showed that the CAR T-cell therapy was much better in terms of overall response rates as well as [progression-free survival],” Dr. Martin said.